Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Luminex, Danaher, Abbott, and More

NEW YORK (GenomeWeb) – Luminex said this week that it has reached an agreement whereby Laboratory Corporation of America is extending its commitment to the Luminex Cystic Fibrosis product line through Dec. 31, 2019. This indicates that LabCorp would maintain at least its current volume of CF testing with Luminex through calendar year 2019.

Luminex also announced this week that its board of directors declared a cash dividend for the third quarter of 2017 of $.06 per share of common stock, payable on Oct. 13 to stockholders of record at the close of business on Sept. 22.

Danaher’s board of directors this week approved a regular quarterly dividend of $.14 per share, payable on Oct. 27 to shareholders of record on Sept. 29.

Abbott this week declared a quarterly dividend of $.27 per share, payable on Nov. 15 to shareholders of record at the close of business on Oct. 13.

Interpace Diagnostics announced this week that the American Medical Association has assigned a new, discreet CPT code to facilitate reimbursement of ThyraMIR, the company's miRNA-based molecular test for indeterminate thyroid nodules. The new code, 0018U, will expedite the process for Interpace in submitting claims and securing reimbursement for the test, the company said.

HTG Molecular Diagnostics announced this week that it expects to complete and file the fourth and final module related to the premarket approval application submission for its HTG EdgeSeq ALKPlus Assay in the second quarter of 2018. The first three modules of the PMA have already been submitted to the US Food and Drug Administration for review. The EdgeSeq ALKPlus is an in vitro diagnostic intended to measure and analyze mRNA ALK gene rearrangements in formalin-fixed, paraffin-embedded lung tumor specimens from patients previously diagnosed with non-small cell lung cancer. It may be used to identify patients eligible for ALK-targeted therapeutics.  

Oxford Genetics announced this week that it has opened its first US office in Boston. This is the company's first office outside of the UK. Oxford Genetics said it is aiming to grow its US commercial team to approximately 10 over the next 18 months, sign collaborative deals, drive sales, and strengthening its customer and technical support offering.

Roswell Park Cancer Institute announced this week that it has joined the Oncology Research Information Exchange Network (ORIEN). ORIEN is an alliance of cancer centers that contribute to a shared databank and collaborate on clinical research with the goal of developing more personalized treatment options for cancer patients.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.